Patents Assigned to ZymoGenetics
  • Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
    Patent number: 7833529
    Abstract: Soluble, secreted tumor necrosis factor receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise one cysteine-rich repeat that is homologous to other tumor necrosis factor receptors, such as transmembrane activator and CAML-interactor (TACI). The polypeptides may be used for detecting ligands, agonists and antagonists. The polypeptides may also be used in methods that modulate B cell activation.
    Type: Grant
    Filed: July 27, 2000
    Date of Patent: November 16, 2010
    Assignee: ZymoGenetics, Inc.
    Inventor: Jane A. Gross
  • Method for expanding hematopoietic cells using cytokine zalpha11 ligand
    Patent number: 7829075
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: October 19, 2006
    Date of Patent: November 9, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • Antibody to mammalian cytokine-like polypeptide-10
    Patent number: 7829089
    Abstract: A mammalian cytokine-like polypeptide, called Mammalian Cytokine-like polypeptide-10, (Zcyto10), polynucleotides encoding the same, antibodies which specifically bind to the polypeptide, and anti-idiotypic antibodies which bind to the antibodies. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets.
    Type: Grant
    Filed: September 1, 2009
    Date of Patent: November 9, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Darrell C. Conklin, Betty A. Haldeman, Angelika Grossmann
  • Method of using interferon-like potein ZCYTO20 (IL-28A) or ZCYTO22(IL-28B) to treat hepatitis B
    Patent number: 7829076
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-? at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: November 9, 2010
    Assignee: ZymoGenetics, LLC
    Inventors: Paul O. Sheppard, Brian A. Fox, Kevin M. Klucher, David W. Taft, Wayne Kindsvogel
  • METHODS OF USING IL-31 ANTAGONISTS IN DISEASES MEDIATED BY CUTANEOUS LYMPHOCYTE ANTIGEN POSITIVE T CELLS
    Publication number: 20100266600
    Abstract: The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population.
    Type: Application
    Filed: March 19, 2010
    Publication date: October 21, 2010
    Applicants: ZymoGenetics, Inc., National Jewish Medical Research Center
    Inventors: Donald Y.M. Leung, Janine Bilsborough, Jane A. Gross
  • Human cytokine receptor
    Patent number: 7812130
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: October 12, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen
  • Human tumor necrosis factor receptor polynucleotides
    Patent number: 7799543
    Abstract: Tumor necrosis factors and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human tumor necrosis factor receptor designated as “Ztnfr12.
    Type: Grant
    Filed: November 13, 2006
    Date of Patent: September 21, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Jane A. Gross, Wenfeng Xu, Randal M. Henne, Francis J. Grant
  • Methods of using IL-31 to treat airway hyper-responsiveness and asthma
    Patent number: 7799323
    Abstract: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proimflammatory cytokines and include administration of the IL-31 agonsit during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
    Type: Grant
    Filed: January 10, 2008
    Date of Patent: September 21, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Janine M. Bilsborough, Eric M. Chadwick, Sherri L. Mudri
  • Soluble IL-17RA/RC fusion proteins
    Patent number: 7790676
    Abstract: Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.
    Type: Grant
    Filed: March 26, 2008
    Date of Patent: September 7, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Steven D. Levin, Mark W. Rixon, Gao Zeren
  • Antibodies that bind both IL-17A and IL-17F and methods of using the same
    Patent number: 7790163
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, an methods of using the same in inflammation.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: September 7, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica Huber
  • Human cytokine receptor
    Patent number: 7790851
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.
    Type: Grant
    Filed: May 4, 2009
    Date of Patent: September 7, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen, Steven D. Hughes
  • IL-17 and IL-23 antagonists and methods of using the same
    Patent number: 7790862
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it's p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: September 7, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Katherine E. Lewis, Scott R. Presnell, James W. West, Robert Mabry, Steven D. Levin
  • PRODUCTION AND PURIFICATION OF IL-29
    Publication number: 20100222552
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.
    Type: Application
    Filed: February 5, 2010
    Publication date: September 2, 2010
    Applicant: ZymoGenetics, LLC
    Inventors: Bruce L. Zamost, Robert M. Dedinsky
  • Use of IL-28 and IL-29 to treat cancer and autoimmune disorders
    Patent number: 7786075
    Abstract: Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics.
    Type: Grant
    Filed: February 12, 2008
    Date of Patent: August 31, 2010
    Assignee: ZymoGenetics, LLC
    Inventors: Sean Doyle, Kevin M. Klucher, Pallavur V. Sivakumar, Wayne R. Kindsvogel, Chung Chan
  • Soluble receptor BR43x2
    Patent number: 7772365
    Abstract: Soluble, secreted tumor necrosis factor receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise one cysteine-rich repeat that is homologous to other tumor necrosis factor receptors, such as transmembrane activator and CAML-interactor (TACI). The polypeptides may be used for detecting ligands, agonists and antagonists. The polypeptides may also be used in methods that modulate B cell activation.
    Type: Grant
    Filed: July 20, 2006
    Date of Patent: August 10, 2010
    Assignee: Zymogenetics, Inc.
    Inventors: Jane A. Gross, Wenfeng Xu, Karen L. Madden, David P. Yee
  • Compositions of IL-21 produced in prokaryotic hosts
    Patent number: 7767199
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-21 are described. The vectors utilize the IL-21 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Using the expression vectors, the IL-21 gene was produced in E. coli to a level of greater than 1 g/L in fed batch fermentation. Also included are OmpT deficient E. coli strains transformed with an IL-21 expression vector.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: August 3, 2010
    Assignee: ZymoGenetics, Inc.
    Inventor: Jeffrey D. Meyer
  • Zalpha11 cytokine receptors
    Patent number: 7763713
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zalpha11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block zalpha11 Ligand activity in vitro and in vivo, and may be used in conjunction with zalpha11 Ligand and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: October 3, 2006
    Date of Patent: July 27, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Julia E. Novak, James W. West, Scott R. Presnell, Richard D. Holly, Andrew J. Nelson
  • Dimeric fusion proteins and materials and methods for producing them
    Patent number: 7763445
    Abstract: Polypeptide fusions, dimeric fusion proteins, and materials and methods for making them are disclosed. One of the polypeptide fusions consists of a non-immunoglobulin polypeptide, a polypeptide linker, a dimerizing domain, and, optionally, a linking polypeptide. Another of the polypeptide fusions consists of a non-immunoglobulin polypeptide, a polypeptide linker, and a second dimerizing domain.
    Type: Grant
    Filed: April 21, 2008
    Date of Patent: July 27, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Margaret D. Moore, Brian A. Fox
  • TACI-IMMUNOGLOBULIN FUSION PROTEINS
    Publication number: 20100183609
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Application
    Filed: October 26, 2009
    Publication date: July 22, 2010
    Applicant: ZymoGenetics, Inc.
    Inventors: Mark W. Rixon, Jane A. Gross
  • Production and purification of IL-29
    Patent number: 7759092
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: July 20, 2010
    Assignee: ZymoGenetics, LLC
    Inventors: Bruce L. Zamost, Robert M. Dedinsky